Hebah Al Khatib

Dr. Hebah Al Khatib


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
NNNico Nagelkerke
Nico Nagelkerke
HAHoussein Ayoub
Houssein Ayoub
PCPeter Coyle
Peter Coyle
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Background: The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated the duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection and protection against severe reinfection, in Qatar, between 28 February 2020 and 5 June 2022. Methods: Three national, matched, retrospective cohort studies were conducted to compare the incidence of SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional hazard regression models. Results: Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% [95% confidence interval (CI): 84.8–86.2%]. Effectiveness peaked at 90.5% (95% CI: 88.4–92.3%) in the 7th month after the primary infection, but waned to ~ 70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and < 10% by the 32nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3–39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of < 10% by the 15th month. Effectiveness of primary infection against severe, critical or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9–98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age. Conclusions: Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.

28 May 2021 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha Benslimane
Fatiha Benslimane
HKHebah Al Khatib
Hebah Al Khatib
RBRoberto Bertollini
Roberto Bertollini
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of people in the shortest time, in situations of limited vaccine supplies and high incidence, could avert more disease cases, hospitalizations and deaths than the current protocol of a second dose shortly after the first dose.

27 May 2022 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
SQSuelen H Qassim
Suelen H Qassim
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
SASawsan AlMukdad
Sawsan AlMukdad
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Qatar experienced a large severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) wave that started on 19 December 2021 and peaked in mid-January, 2022. 1 We investigated effects of Omicron subvariant (BA.1 and BA.2), previous vaccination and prior infection on infectiousness of Omicron infections, between 23 December 2021 and 20 February 2022. Incidence was initially dominated by BA.1, but within a few days, BA.2 predominated ( Supplementary Figure S1 and Supplementary Section S1, Supplementary Appendix).

1 July 2023 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
SASawsan AlMukdad
Sawsan AlMukdad
JFJeremy S Faust
Jeremy S Faust
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains. 1 We estimated this vaccine’s effectiveness against SARS-CoV-2 infection.

20 July 2023 in eClinicalMedicine
Verified
Journal Article
Open access
SQSuelen H. Qassim
Suelen H. Qassim
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
PCPeter Coyle
Peter Coyle
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Waning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination are defined, respectively, as the overall protection against reinfection or against breakthrough infection at a given point in time in a given population. We estimated these population immunities in Qatar's population between July 1, 2020 and November 30, 2022, to discern generic features of the epidemiology of SARS-CoV-2. Effectiveness of previous infection, mRNA primary-series vaccination, and mRNA booster (third-dose) vaccination in preventing infection were estimated, month by month, using matched, test-negative, case–control studies. Previous-infection effectiveness against reinfection was strong before emergence of Omicron, but declined with time after a wave and rebounded after a new wave. Effectiveness dropped after Omicron emergence from 88.3% (95% CI: 84.8–91.0%) in November 2021 to 51.0% (95% CI: 48.3–53.6%) in December 2021. Primary-series effectiveness against infection was 84.0% (95% CI: 83.0–85.0%) in April 2021, soon after introduction of vaccination, before waning gradually to 52.7% (95% CI: 46.5–58.2%) by November 2021. Effectiveness declined linearly by ∼1 percentage point every 5 days. After Omicron emergence, effectiveness dropped from 52.7% (95% CI: 46.5–58.2%) in November 2021 to negligible levels in December 2021. Booster effectiveness dropped after Omicron emergence from 83.0% (95% CI: 65.6–91.6%) in November 2021 to 32.9% (95% CI: 26.7–38.5%) in December 2021, and continued to decline thereafter. Effectiveness of previous infection and vaccination against severe, critical, or fatal COVID-19 were generally >80% throughout the study duration. High population immunity against infection may not be sustained beyond a year, but population immunity against severe COVID-19 is durable with slow waning even after Omicron emergence. The Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core, both at 10.13039/100019460 Weill Cornell Medicine-Qatar , 10.13039/501100004397 Ministry of Public Health , 10.13039/100007833 Hamad Medical Corporation , 10.13039/100019475 Sidra Medicine , Qatar Genome Programme, Qatar University Biomedical Research Center, and Qatar University Internal Grant ID QUCG-CAS-23/24-114.

22 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
HAHeba N. Altarawneh
Heba N. Altarawneh
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
PTPatrick Tang
Patrick Tang
MHMohammad R. Hasan
Mohammad R. Hasan
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
BACKGROUND Protection offered by five different forms of immunity, combining natural and vaccine immunity, was investigated against SARS-CoV-2 Omicron symptomatic BA.1 infection, symptomatic BA.2 infection, BA.1 hospitalization and death, and BA.2 hospitalization and death, in Qatar, between December 23, 2021 and February 21, 2022. METHODS Six national, matched, test-negative case-control studies were conducted to estimate effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine, mRNA-1273 (Moderna) vaccine, natural immunity due to prior infection with pre-Omicron variants, and hybrid immunity from prior infection and vaccination. RESULTS Effectiveness of only prior infection against symptomatic BA.2 infection was 46.1% (95% CI: 39.5-51.9%). Effectiveness of only two-dose BNT162b2 vaccination was negligible at -1.1% (95% CI: -7.1-4.6), but nearly all individuals had received their second dose several months earlier. Effectiveness of only three-dose BNT162b2 vaccination was 52.2% (95% CI: 48.1-55.9%). Effectiveness of hybrid immunity of prior infection and two-dose BNT162b2 vaccination was 55.1% (95% CI: 50.9-58.9%). Effectiveness of hybrid immunity of prior infection and three-dose BNT162b2 vaccination was 77.3% (95% CI: 72.4-81.4%). Meanwhile, prior infection, BNT162b2 vaccination, and hybrid immunity all showed strong effectiveness >70% against any severe, critical, or fatal COVID-19 due to BA.2 infection. Similar levels and patterns of effectiveness were observed for BA.1 and for the mRNA-1273 vaccine. CONCLUSIONS There are no discernable differences in the effects of prior infection, vaccination, and hybrid immunity against BA.1 versus BA.2. Hybrid immunity resulting from prior infection and recent booster vaccination confers the strongest protection against either subvariant. Vaccination enhances protection of those with a prior infection.